Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study
Authors
Keywords
-
Journal
BLOOD
Volume 121, Issue 3, Pages 537-545
Publisher
American Society of Hematology
Online
2012-11-21
DOI
10.1182/blood-2012-04-425512
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation
- (2012) B. Psaila et al. BLOOD
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
- (2011) C. Neunert et al. BLOOD
- Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents
- (2011) Waleed Ghanima et al. BRITISH JOURNAL OF HAEMATOLOGY
- Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia
- (2011) Patrick F. Fogarty et al. CURRENT MEDICAL RESEARCH AND OPINION
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents
- (2010) W. Bao et al. BLOOD
- Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study
- (2010) Marianne T. Severinsen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database
- (2010) A. Sarpatwari et al. HAEMATOLOGICA
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
- (2010) Gregory Cheng et al. LANCET
- Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
- (2010) David J. Kuter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura
- (2009) J. Pruemer AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome
- (2009) B. Will et al. BLOOD
- International consensus report on the investigation and management of primary immune thrombocytopenia
- (2009) D. Provan et al. BLOOD
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
- (2009) James B Bussel et al. LANCET
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
- (2008) J. B. Bussel et al. BLOOD
- The effect of anti-CD40 ligand in immune thrombocytopenic purpura
- (2008) Vivek L. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Autoimmune thrombocytopenia in non-Hodgkin's lymphomas
- (2008) A. W. Hauswirth et al. HAEMATOLOGICA
- Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
- (2008) Susan D Mathias et al. Health and Quality of Life Outcomes
- Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
- (2008) David J Kuter et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now